Jul 18, 2019 12:00 PM


Trudy Oliver, PhD and Milind Chalishazar

Research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into understanding potential new treatment options for MYC-driven tumors, a distinct subtype of small cell lung cancer. MYC is a protein that drives cell proliferation, growth, death, and self-renewal. The results were published this month in Clinical Cancer Research, a publication of the American Association for Cancer Research. 

Lung cancer is the leading cause of cancer death among men and women in Utah and the United States. Often, symptoms do not appear until the disease is advanced. Therefore, research studies toward better practices to prevent, find, and treat lung cancer are paramount.

Trudy Oliver, PhD, an investigator at HCI and associate professor of oncological sciences at the U of U, led the study. “We conducted this study to determine whether metabolic weaknesses exist between small cell lung cancer subtypes and whether we can exploit them,” said Oliver.

In 2017, Dr. Oliver’s research created the first known replica of a small cell tumor caused by a protein called MYC and discovered that these tumors are more aggressive, spread faster, and respond differently to therapy. Building on that knowledge, her team delivered ADI-PEG20, an enzyme that breaks down the amino acid arginine, in MYC-positive genetically-engineered mouse models and human patient-derived cells, resulting in a promising breakthrough.

“We targeted MYC-positive tumors and saw remarkable results, including tumor shrinkage and tumor death and a significant extension in overall survival,” says Milind Chalishazar, a PhD student in the Oliver lab, who conducted the laboratory work. “This suggests that we have identified a potential new therapeutic strategy that will improve lung cancer outcomes in the future.” 

Currently, small cell lung cancer accounts for approximately 10-15% of lung cancers. It is rarer and more aggressive than non-small cell lung cancer. Standard chemotherapy treatment for small-cell cancer has remained similar for the last 40 years. Only minor progress in treatment options for patients who develop resistance to chemotherapy in small cell lung cancer has occurred.

“The lack of new treatment options for patients with small cell lung cancer often results in poor survival rates,” said Oliver. “This research will inform clinical trials we are currently designing.”

The study is supported by the Lung Cancer Research Foundation through a William C. Rippe Award for Distinguished Research in Lung Cancer to Dr. Oliver, the National Cancer Institute grant P30 CA042014, and Huntsman Cancer Foundation.

Media Contact

Debby Rogers
Public Relations - Huntsman Cancer Institute
801-587-7639

lung cancer cancer research

About Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute (HCI) at the University of Utah is the official cancer center of Utah. The cancer campus includes a state-of-the-art cancer specialty hospital as well as two buildings dedicated to cancer research. HCI treats patients with all forms of cancer and is recognized among the best cancer hospitals in the country by U.S. News and World Report. As the only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center in the Mountain West, HCI serves the largest geographic region in the country, drawing patients from Utah, Nevada, Idaho, Wyoming, and Montana. More genes for inherited cancers have been discovered at HCI than at any other cancer center in the world, including genes responsible for hereditary breast, ovarian, colon, head, and neck cancers, along with melanoma. HCI manages the Utah Population Database, the largest genetic database in the world, with information on more than 11 million people linked to genealogies, health records, and vital statistics. HCI was founded by Jon M. and Karen Huntsman.